Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on protein homeostasis via the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe autoimmune diseases. Additionally, KZR-261 is the first clinical candidate for the treatment of cancer from our protein secretion program and is undergoing IND-enabling activities for the program.
Pharmaceutical Preparation Manufacturing (325412)
Pharmaceutical Preparations (2834)